62
Participants
Start Date
July 5, 2023
Primary Completion Date
October 1, 2026
Study Completion Date
October 1, 2029
Durvalumab
It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
Gemcitabine
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
Nab paclitaxel
Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
Tremelimumab
Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
Propranolol
Competitively blocks both β1 and β2 adrenergic receptors.
Cisplatin
cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
RECRUITING
Cross Cancer Institute, Edmonton
AHS Cancer Control Alberta
OTHER